The evaluation of changes in peripheral neuropathy and quality-of-life using low-frequency electrostimulation in patients treated with chemotherapy for breast cancer: a study protocol

Background: This study examined the effect of a portable low-frequency electrostimulation (ES) device on patients diagnosed with chemotherapy-induced peripheral neuropathy (CIPN) immediately after chemotherapy for breast cancer. Methods: A single-center, randomized, placebo-controlled trial was conducted. A total of 72 patients newly diagnosed with CIPN were enrolled and randomly placed into the ES (n = 36) or the sham ES group (SES; n = 36). Duloxetine or pregabalin was prescribed to all participants from the initial assessment. The devices for 14 days, at least twice a day, for at least 120 minutes. The primary outcomes were the overall intensities of the CIPN symptoms as assessed using Numerical Rating Scale (NRS). Secondary outcomes included Total Neuropathy Score (TNS), European Organization for Research and Treatment of Cancer Quality of Life (EORTC-QLQ), Chemotherapy-Induced Peripheral Neuropathy 20 (CIPN20), Functional Assessment of Cancer Therapy-Breast (FACT-B), and Instrument on Pattern Identification and Evaluation for CIPN (IPIE-CIPN). Results: No differences in NRS scores were found between the patients in the ES and the SES group ( P = 0.267). Patients in both groups showed significantly reduced CIPN intensities (ES P < .001; SES P < .001). No significant differences between the groups were found in TNS, EORTC-QLQ, CIPN20, and FACT-B. The general symptoms of CIPN diagnosed as cold arthralgia showed significance only in the ES group ( P = .006). Conclusion: Compared with a placebo, the effectiveness of the low-frequency ES device with pharmacological intervention was not significantly different, but a therapeutic effect was possible.

Download Full-text

A randomized, placebo-controlled trial evaluating changes in peripheral neuropathy and quality of life by using low-frequency electrostimulation on breast cancer patients treated with chemotherapy

Integrative Medicine Research ◽

10.1016/j.imr.2020.100518 ◽

2020 ◽

Vol 9 ◽

pp. 100518

Author(s):

Si-Yeon Song ◽

Ji-hye Park ◽

Jin Sun Lee ◽

Je Ryong Kim ◽

Eun Hee Sohn ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Peripheral Neuropathy ◽

Cancer Patients ◽

Controlled Trial ◽

Low Frequency ◽

Breast Cancer Patients

Download Full-text

Determination of the Influence of Peripheral Neuropathy Symptoms on Quality of Life in Breast Cancer Patients Receiving Paclitaxel: Prospective Cross Sectional Study With Four Follow-ups

10.21203/rs.3.rs-984164/v1 ◽

2021 ◽

Author(s):

BERNA KURT ◽

ZEYNEP SİPAHİ KARSLI ◽

BERNA ÖMÜR ÇAKMAK ÖKSÜZOĞLU ◽

EMİNE ÖZTÜRK ◽

NESLİHAN DEMİRÖRS ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Peripheral Neuropathy ◽

Assessment Tool ◽

Life Questionnaire ◽

Breast Cancer Patients ◽

Cross Sectional ◽

Quality Of Life Questionnaire

Abstract Background The objective of this study is to evaluate the impact of peripheral neuropathy on the quality of life of breast cancer patients throughout with monthly follow-up during 4 months of paclitaxel treatment.Material and methods The research was conducted with a prospective cross sectional with four follow-ups descriptive design. The study population consisted of female patients with breast cancer at Ankara Oncology Training and Research Hospital between August 2018 and January 2019. Data were collected the ‘’Patient Information Form’’,‘’EORTC C30 Cancer Quality Of Life Questionnaire’’ and ‘’Chemotherapy-Induced Peripheral Neuropathy Assessment Tool’’. The study was undertaken in accordance with the STROBE checklist for cross-sectional studies. Results Of 79 patients included in the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool except for the general activity subdimension were statistically significant in the ratings of 2nd, compared to 1st; 3rd compared to 1st and 2nd; 4th compared to 1st, 2nd, and 3rd follow-up periods. The overall mean of EORTC C30 Cancer Quality of Life Questionnaire, functional subdimension, symptom severity, and general well-being in the evaluations of 2nd, compared with 1st; 3rd compared with 1st and 2nd; 4th compared with 1st, 2nd, and 3rd follow-up periods it was found that the mean values of symptom that decreased gradually were statistically significant.Conclusion The neuropathy scale was found to be higher in 2nd, 3rd, 4th follow-up periods than in 1st follow-up. Also, EORTC C30 Cancer QLQ subdimensions were high initially but gradually decreased after the fourth cycle. Thus, it was found that the increase in neuropathy symptoms negatively affects the quality of life.

Download Full-text

Taxane-induced peripheral neuropathy and quality of life in breast cancer patients

Journal of Oncology Pharmacy Practice ◽

10.1177/1078155219898511 ◽

2020 ◽

Vol 26 (6) ◽

pp. 1421-1428

Author(s):

Ebrahim Salehifar ◽

Ghasem Janbabaei ◽

Abbas Alipour ◽

Nasim Tabrizi ◽

Razieh Avan

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Health Status ◽

Peripheral Neuropathy ◽

Global Health ◽

Cancer Patients ◽

Physical Functioning ◽

Role Functioning ◽

Breast Cancer Patients

Purpose Taxane-induced peripheral neuropathy (TIPN) is a common and bothersome toxicity. This study aimed to determine the incidence and severity of TIPN in patients with breast cancer and to investigate the relationship between TIPN and quality of life. Methods A total of 82 breast cancer patients with TIPN symptoms were included in this study. The criteria of National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE v4.03) and the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30, version 3.0) were used to evaluate grading of sensory neuropathy and quality of life, respectively. Analysis of the data was done by IBM SPSS statistics version 23. Results A total of 346 patients received taxane-based chemotherapy and 82 patients (23.7%) experience TIPN. The mean (SD) global health status/quality of life, physical functioning, role functioning, and pain subscales were 60.63 (5.26), 80.64 (9.05), 81.77 (10.41), and 43.88 (11.27), respectively. There were significant negative correlations between global health status/quality of life, physical functioning, and role functioning subscales with the grade of neuropathy (r = −0.33, −0.80, and −0.61, respectively) and positive correlation between pain subscale and the grade of neuropathy (r = 0.70). Conclusion This study shows a clear association between TIPN and worsened quality of life. These findings emphasize on detecting and management of TIPN in an effort to improve the quality of life of breast cancer patients.

Download Full-text

Telehealth system (e-CUIDATE) to improve quality of life in breast cancer survivors: rationale and study protocol for a randomized clinical trial

Trials ◽

10.1186/1745-6215-14-187 ◽

2013 ◽

Vol 14 (1) ◽

pp. 187 ◽

Cited By ~ 21

Author(s):

Noelia Galiano-Castillo ◽

Angelica Ariza-García ◽

Irene Cantarero-Villanueva ◽

Carolina Fernández-Lao ◽

Lourdes Díaz-Rodríguez ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Clinical Trial ◽

Cancer Survivors ◽

Randomized Clinical Trial ◽

Study Protocol ◽

Breast Cancer Survivors ◽

Improve Quality

Download Full-text

The post-mastectomy syndrome: the secondary lympedema after the combined treatment of breast cancer (the literature review and own results)

Modern Oncology ◽

10.26442/1815-1434_2018.2.45-49 ◽

2018 ◽

Vol 20 (2) ◽

pp. 45-49 ◽

Cited By ~ 1

Author(s):

A M Stepanova ◽

A M Merzlyakova ◽

M M Khulamhanova ◽

O P Trofimova

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Electrical Stimulation ◽

Literature Review ◽

Emotional State ◽

Combined Treatment ◽

Low Frequency ◽

Complex Treatment ◽

Magnetic Therapy

The post-mastectomy syndrome and lymphedema after the combined treatment of breast cancer, significantly worsen the quality of life of patients, their psycho - emotional state. The treatment of this disease is always combined in nature, and involves elements of the Complex Decongestive Therapy, pneumatic compression, mild electrical stimulation and low-frequency magnetic therapy. The best results of therapy are achieved with early detection and treatment. Complex treatment of lymphedema does not affect the course of cancer.

Download Full-text